MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dumuis, A.
Right arrow Articles by Bockaert, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dumuis, A.
Right arrow Articles by Bockaert, J.

Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture

A Dumuis, M Sebben and J Bockaert

Centre CNRS-INSERM de Pharmacologie-Endocrinologie, Montpellier, France.

Serotonin (5-hydroxytryptamine, 5-HT) inhibited the formation of cAMP promoted by vasoactive intestinal polypeptide, plus forskolin, in mouse hippocampal and cortical neurons in primary culture. The rank order of potencies of classical 5-HT1 agonists in inhibiting cAMP formation in hippocampal neurons was 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH- DPAT) greater than 5-carboxamidotryptamine (5-CT) greater than d- lysergic acid diethylamide greater than 5-HT greater than 5-methoxy-N,N- dimethyltryptamine (5-MeO-N,N-DMT) greater than RU 24969 greater than ipsapirone greater than bufotenine greater than buspirone [half-maximal efficacy (EC50) = 7, 18, 30, 52, 90, 102, 100, 110, and 128 nM, respectively]. All the tryptamine derivatives substituted in position 5 of the indol were potent agonists [5-HT, 5-CT, 5-MeO-N,N-DMT, 5- methoxytryptamine, and bufotenine], whereas tryptamine, N- methyltryptamine, and N,N-dimethyltryptamine were poor agonists. The most potent antagonists tested were spiperone, (+/-)-pindolol, (+/-)- cyanopindolol, WB4101, and methiothepin, the affinity of spiperone for this receptor being 22 nM. In contrast, ketanserin, a specific 5-HT2 antagonist, and 5-HT3-selective drugs (ICS 205 930 and MDL 72222) were very weak in antagonizing the 5-HT-inhibited cAMP formation. The pharmacological profiles of 5-HT receptors mediating the inhibition of cAMP formation indicate that these receptors correspond to the 5-HT1A- binding site subtypes. Experiments with the Bordetella pertussis toxin indicate that the 5-HT1A receptor mediating inhibition of cAMP production involves a pertussis toxin-sensitive GTP-binding protein. In the absence of VIP, cAMP formation could be stimulated through a 5-HT receptor, but the specific 5-HT1A agonists, 8-OH-DPAT and RU 24969 did not stimulate cAMP production. These results suggest that in mouse embryonic hippocampal neurons, the 5-HT1A receptors, which are negatively coupled to adenylate cyclase, are distinct from the receptor positively coupled to this enzyme. The pharmacological characterization of the 5-HT receptor negatively coupled to adenylate cyclase in mouse embryonic cortical neurons indicates that it differs from the 5-HT1A receptor found in hippocampal neurons. Its main differences with the 5- HT1A receptor in hippocampal neurons are as follows: 1) 8-OH-DPAT was only a poor partial agonist in cortical neurons, whereas it was the best full agonist in hippocampal neurons; and 2) metergoline and methysergide as well as the anxiolytic drugs, ipsapirone and buspirone, which were potent agonists in hippocampal neurons, were competitive antagonists in cortical neurons.(ABSTRACT TRUNCATED AT 400 WORDS)

Volume 33, Issue 2, pp. 178-186, 02/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
U. Renner, K. Glebov, T. Lang, E. Papusheva, S. Balakrishnan, B. Keller, D. W. Richter, R. Jahn, and E. Ponimaskin
Localization of the Mouse 5-Hydroxytryptamine1A Receptor in Lipid Microdomains Depends on Its Palmitoylation and Is Involved in Receptor-Mediated Signaling
Mol. Pharmacol., September 1, 2007; 72(3): 502 - 513.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
Y. Odagaki, R. Toyoshima, and T. Yamauchi
Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTP{gamma}S binding
J Psychopharmacol, May 1, 2005; 19(3): 235 - 241.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
E. Papoucheva, A. Dumuis, M. Sebben, D. W. Richter, and E. G. Ponimaskin
The 5-Hydroxytryptamine(1A) Receptor Is Stably Palmitoylated, and Acylation Is Critical for Communication of Receptor with Gi Protein
J. Biol. Chem., January 30, 2004; 279(5): 3280 - 3291.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. F. Liu, M. H. Ghahremani, M. M. Rasenick, K. H. Jakobs, and P. R. Albert
Stimulation of cAMP Synthesis by Gi-coupled Receptors upon Ablation of Distinct Galpha i Protein Expression. Gi SUBTYPE SPECIFICITY OF THE 5-HT1A RECEPTOR
J. Biol. Chem., June 4, 1999; 274(23): 16444 - 16450.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
C. G. Cardenas, L. P. D. Mar, and R. S. Scroggs
Two Parallel Signaling Pathways Couple 5HT1A Receptors to N- and L-Type Calcium Channels in C-Like Rat Dorsal Root Ganglion Cells
J Neurophysiol, June 1, 1997; 77(6): 3284 - 3296.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. A. Chen and D. R. Manning
Regulation of Galpha i Palmitoylation by Activation of the 5-Hydroxytryptamine-1A Receptor
J. Biol. Chem., July 28, 2000; 275(31): 23516 - 23522.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics